Critical Analysis: Biosig Technologies (NASDAQ:STEX) versus Nanovibronix (NASDAQ:FEED)

Biosig Technologies (NASDAQ:STEX) and Nanovibronix (NASDAQ:FEED) are both small-cap manufacturing companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.

Profitability

This table compares Biosig Technologies and Nanovibronix’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	N/A	-64.96%
Nanovibronix	-275.12%	-24.78%	-19.24%

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Biosig Technologies and Nanovibronix, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1	0	0	0	1.00
Nanovibronix	1	0	0	0	1.00

Volatility & Risk

Biosig Technologies has a beta of 1.5, suggesting that its share price is 50% more volatile than the S&P 500. Comparatively, Nanovibronix has a beta of 2.21, suggesting that its share price is 121% more volatile than the S&P 500.

Institutional and Insider Ownership

7.2% of Biosig Technologies shares are owned by institutional investors. Comparatively, 16.4% of Nanovibronix shares are owned by institutional investors. 52.7% of Biosig Technologies shares are owned by company insiders. Comparatively, 1.4% of Nanovibronix shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Biosig Technologies and Nanovibronix”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biosig Technologies	$40,000.00	9,815.40	-$10.33 million	($1.35)	-1.82
Nanovibronix	$2.69 million	1.11	-$3.70 million	($41.74)	-0.07

Nanovibronix has higher revenue and earnings than Biosig Technologies. Biosig Technologies is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.

Summary

Nanovibronix beats Biosig Technologies on 6 of the 11 factors compared between the two stocks.

About Biosig Technologies

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company’s proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.

About Nanovibronix

NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.